The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.
Indomethacin and sulindac were used as tools to study the role of renal and/or systemic prostaglandins in the pharmacological response to atenolol. Patients receiving chronic treatment with atenolol 100 mg received indomethacin 50 mg twice daily or sulindac 200 mg twice daily in a randomised crossover trial. Indomethacin significantly reduced the antihypertensive action of atenolol while sulindac had no effect. The role that systemic and/or renal prostaglandins may play in the antihypertensive action of atenolol is discussed with reference to renal PGI2 production and inhibition of platelet cyclo-oxygenase.
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000328:Adult; D001262:Atenolol / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D007192:Indenes / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012083:Renin / Q000097:blood; D013467:Sulindac / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000097:blood
D007192:Indenes; D013467:Sulindac; D001262:Atenolol; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D012083:Renin; D007213:Indomethacin